{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:17Z","timestamp":1758937217535,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.leukres.2020.106440","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T21:13:51Z","timestamp":1598303631000},"page":"106440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Examination of clinically-derived p210 BCR\/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-8925","authenticated-orcid":false,"given":"Bryan T.","family":"Ciccarelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian P.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106440_bib0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106440_bib0010","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1038\/onc.2013.362","article-title":"Rho guanine nucleotide exchange factors: regulators of RhoGTPase activity in development and disease","volume":"33","author":"Cook","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrm1587","article-title":"GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors","volume":"6","author":"Rossman","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2020.106440_bib0020","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1042\/BST20120103","article-title":"Rho family GTPases","volume":"40","author":"Hall","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.leukres.2020.106440_bib0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrm.2016.67","article-title":"Regulating RhoGTPases and their regulators","volume":"8","author":"Hodge","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2020.106440_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/biof.1155","article-title":"Rho GTPases and cancer","volume":"40","author":"Li","year":"2014","journal-title":"Biofactors"},{"key":"10.1016\/j.leukres.2020.106440_bib0035","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29019","article-title":"Rho GTPases modulate malignant transformation of tumor cells","volume":"5","author":"Orgaz","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.leukres.2020.106440_bib0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOH.0b013e32832c4b80","article-title":"Rho GTPases in hematopoietic stem cell functions","volume":"16","author":"Cancelas","year":"2009","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.leukres.2020.106440_bib0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/21541248.2016.1173767","article-title":"Deregulation of rho GTPases in cancer","volume":"7","author":"Porter","year":"2016","journal-title":"Small GTPases"},{"key":"10.1016\/j.leukres.2020.106440_bib0050","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.exphem.2016.09.002","article-title":"Variegated RHOA mutations in human cancers","volume":"44","author":"Kataoka","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2020.106440_bib0055","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1038\/onc.2016.473","article-title":"Rho GTPases: Anti- or pro-neoplastic targets?","volume":"36","author":"Zandvakili","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0060","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1038\/s41388-019-0963-7","article-title":"Rho GTPases in cancer: friend or foe?","volume":"38","author":"Svensmark","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0065","doi-asserted-by":"crossref","first-page":"25150","DOI":"10.1074\/jbc.M800882200","article-title":"Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification","volume":"283","author":"Roberts","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2020.106440_bib0070","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1200\/JCO.2005.09.005","article-title":"Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes","volume":"23","author":"Cortes","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106440_bib0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-008-0536-2","article-title":"Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study","volume":"87","author":"Ravoet","year":"2008","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106440_bib0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09165.x","article-title":"The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML","volume":"158","author":"Burnett","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106440_bib0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2020.106440_bib0090","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106440_bib0095","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/ijo.2017.4093","article-title":"Rho GTPases as therapeutic targets in cancer (Review)","volume":"51","author":"Cardama","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.leukres.2020.106440_bib0100","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/sj.onc.1210933","article-title":"Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs","volume":"27","author":"Daubon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0105","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.onc.1210841","article-title":"The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation","volume":"27","author":"Sahay","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2012.351","article-title":"Contributions of the RhoGEF activity of p210 BCR\/ABL to disease progression","volume":"27","author":"Tala","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106440_bib0115","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/sj.onc.1206626","article-title":"Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl","volume":"22","author":"Harnois","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0120","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2020.106440_bib0125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.18388\/abp.2004_3568","article-title":"Influence of BCR\/ABL fusion proteins on the course of Ph leukemias","volume":"51","author":"Telegeev","year":"2004","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.leukres.2020.106440_bib0130","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106440_bib0135","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1038\/sj.onc.1205678","article-title":"p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr","volume":"21","author":"Korus","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0140","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/0008-5472.CAN-06-0536","article-title":"Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover","volume":"66","author":"Olabisi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106440_bib0145","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2020.106440_bib0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428190701713689","article-title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"49","author":"Li","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106440_bib0155","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1074\/jbc.C000126200","article-title":"Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck","volume":"275","author":"Lionberger","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2020.106440_bib0160","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2020.106440_bib0165","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106440_bib0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0165-4608(96)00413-X","article-title":"p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis","volume":"98","author":"Stuppia","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.leukres.2020.106440_bib0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0145-2126(95)00024-I","article-title":"Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis","volume":"19","author":"Guinn","year":"1995","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2020.106440_bib0180","first-page":"6588","article-title":"Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p","volume":"52","author":"Nakai","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106440_bib0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.1994.tb04938.x","article-title":"Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia","volume":"87","author":"Nakai","year":"1994","journal-title":"Br. J. Haematol."},{"year":"2013","series-title":"The Biology of Cancer","author":"Weinberg","key":"10.1016\/j.leukres.2020.106440_bib0190"},{"key":"10.1016\/j.leukres.2020.106440_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006958","article-title":"Replication fork slowing and stalling are distinct, checkpoint-independent consequences of replicating damaged DNA","volume":"13","author":"Iyer","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.leukres.2020.106440_bib0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/35044005","article-title":"The DNA damage response: putting checkpoints in perspective","volume":"408","author":"Zhou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2020.106440_bib0205","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrm1493","article-title":"Checking on DNA damage in S phase","volume":"5","author":"Bartek","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2020.106440_bib0210","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106440_bib0215","doi-asserted-by":"crossref","first-page":"25217","DOI":"10.18632\/oncotarget.4611","article-title":"Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes I\u03baB\u03b1 mediated p53 nuclear exclusion","volume":"6","author":"Crivellaro","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2020.106440_bib0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2020.106440_bib0225","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/sj.onc.1205424","article-title":"BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor","volume":"21","author":"Pierce","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2020.106440_bib0230","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106440_bib0235","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1182\/blood-2008-04-148791","article-title":"BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias","volume":"112","author":"Jones","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106440_bib0240","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106440_bib0245","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1128\/MCB.22.19.6895-6905.2002","article-title":"RhoGEF specificity mutants implicate RhoA as a target for Dbs transformation","volume":"22","author":"Cheng","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2020.106440_bib0250","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1182\/blood.V91.10.3927.3927_3927_3934","article-title":"Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression","volume":"91","author":"Klucher","year":"1998","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:47Z","timestamp":1758934847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620301454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"alternative-id":["S0145212620301454"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106440","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examination of clinically-derived p210 BCR\/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106440"}}